Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
Department of Pediatrics, Division of Hematology/Oncology, University of Florida College of Medicine, Gainesville, FL, United States.
Front Immunol. 2022 Feb 22;13:846346. doi: 10.3389/fimmu.2022.846346. eCollection 2022.
Advances from novel adoptive cellular therapies have yet to be fully realized for the treatment of children and young adults with solid tumors. This review discusses the strategies and preliminary results, including T-cell, NK-cell and myeloid cell-based therapies. While each of these approaches have shown some early promise, there remain challenges. These include poor trafficking to the tumor as well as a hostile tumor microenvironment with numerous immunosuppressive mechanisms which result in exhaustion of cellular therapies. We then turn our attention to new strategies proposed to address these challenges including novel clinical trials that are ongoing and in development.
新型过继细胞疗法在治疗儿童和青少年实体瘤方面的进展尚未完全实现。本文讨论了这些策略和初步结果，包括 T 细胞、自然杀伤 (NK) 细胞和髓样细胞疗法。虽然这些方法都有一定的早期前景，但仍存在一些挑战。这些挑战包括细胞疗法向肿瘤的转移不良，以及肿瘤微环境中存在多种免疫抑制机制，导致细胞疗法衰竭。然后，我们将注意力转向正在进行和开发中的新策略，包括新的临床试验。
